Biosimilars Market Regional Analysis:
Europe biosimilars market is estimated to account for largest revenue share by the end of 2034. The growth of the market can be attributed to presence of a strong healthcare network in the region, and the growing number of hospitals and diseases. As per the reported data, nearly 10 percent of the total population in the United States were suffering from diabetes in the year 2021. Moreover, the rising awareness of biosimilars amongst the healthcare service providers, along with surge in prescribing biosimilars, is anticipated to drive the market growth. Furthermore, the market revenue is propeled by volume of biosimilar prescribing has generated high savings from biosimilar competition.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of biosimilars is evaluated at USD 32.55 billion.
Biosimilars Market size was over USD 28.61 billion in 2024 and is poised to exceed USD 128.4 billion by 2034, growing at over 16.2% CAGR during the forecast period i.e., between 2025-2034.
Europe is expected to dominate largest industry share by 2034.
The key market players include Biocon Limited, Amgen Inc., Novartis AG, Intas Pharmaceuticals Ltd., BioXpress Therapeutics SA, Genor Biopharma Co. Ltd, Allergan plc (AbbVie Inc.), Coherus BioSciences, Inc., Pfizer Inc., Reliance Life Sciences Private Limited.
